GSK’s Exdensur receives Japan’s MHLW approval for severe asthma and chronic rhinosinusitis with nasal polyps: London, UK Wednesday, January 7, 2026, 10:00 Hrs [IST] GSK plc an ...
A small prospective, double-blind study in children with IgE-mediated cow’s milk allergy (CMA) found that heated cow’s milk ...
The approval is based on two placebo-controlled phase 3 studies, which showed mepolizumab significantly reduced the annualised rate of moderate/severe exacerbations and time to first moderate/severe ...
TipRanks on MSN
Apogee Therapeutics reports positive Phase 1b asthma results
Apogee Therapeutics ( ($APGE) ) has provided an announcement. On January 6, 2026, Apogee Therapeutics reported positive interim results from a ...
A new study published in the International Journal of General Medicine showed that by focusing on mast cells and inflammatory ...
GSK has secured approval in Japan for Exdensur (depemokimab), the country’s first ultra-long-acting biologic for severe asthma and chronic rhinosinusitis with nasal polyps. Approved by Japan’s ...
Throughout 2025, AbbVie’s Skyrizi and Johnson & Johnson’s Tremfya were mainstays at the top of the monthly TV drug ad ...
Bambusa Therapeutics, Inc., a clinical-stage biotechnology company pioneering next-generation bispecific antibodies ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback